|Description||Flavopiridol hydrochloride competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA.|
|B0084-083124||100 mg||$298||In stock|
|Related CAS||146426-40-6 (free base)|
|Synonyms||NSC 649890 HCl|
KH-CB19, a CLK1/CLK4 inhibitor, has been found to probably restrain the phosphorylation of serine- and arginine-rich (SR) proteins. IC50: 20 nM for CLK1.
Palbociclib, also known as PD0332991, is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic acti...
Senexin A is a selective Cell division protein kinase 8 (CDK8) inhibitor with IC50 value of 280 nM. Senexin A can bind to cdk19 in an ATP-competitive manner and...
Abemaciclib mesylate is a CDK inhiibitor with selectivity for CDK4 and CDK6. It was approved for the treatment of advanced or metastatic breast cancers.
Seliciclib is an orally bioavailable, small-molecule cyclin-dependent kinase (CDK) inhibitor with potential proapoptotic and antineoplastic activities. Selicicl...
Abemaciclib is orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potentia...
Dinaciclib, also known as SCH727965, is a potent CDK inhibitor with potential antineoplastic activity. Dinaciclib selectively inhibits cyclin dependent kinases ...
AMG-925 is a potent, selective, and bioavailable FLT3/cyclin-dependent kinase 4 (CDK4) dual kinase inhibitor. AMG 925 inhibited AML xenograft tumor growth by 96...
LOR-253 is a novel small molecule with potent anti-tumor activity in cancer cells via induction of the gene that expresses the Krüppel-like factor 4 (KLF4) mast...
BS-181 HCl is a highly selective CDK7 inhibitor with IC50 of 21 nM. It is more than 40-fold selective for CDK7 than CDK1, 2, 4, 5, 6, or 9.
BS-181 is a highly selective CDK inhibitor for CDK7 with an IC(50) of 21 nmol/L. Testing of other CDKs as well as another 69 kinases showed that BS-181 only inh...
Purvalanol A is a potent CDK inhibitor, which effectively suppresses Src-mediated transformation by inhibiting both CDKs and c-Src. indicating that the activati...
Flavopiridol hydrochloride competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM. It is 7.5-fold more selective for CDK1/2/...
CGP-79807 is a potent CDC2 protein kinase inhibitor that originated by Novartis. In Sep 2000, Preclinical development for Cancer in Switzerland was on-going, bu...
CDK9-IN-6, one of the CDK9 inhibitors, probably have potential activity in influencing cell cycle of T-type cells.
NVP-LCQ195 is a small molecule heterocyclic inhibitor of CDK1, CDK2, CDK3 and CDK5. It induced cell cycle arrest and eventual apoptotic cell death of MM cells, ...
NU2058 is a potent CDK inhibitor. which has CDK2 IC(50)=17 microM and CDK1 IC(50)=26 microM.
LDC4297 is a potent and selective cyclin-dependent protein kinase 7 (CDK7) inhibitor with an IC50 of 0.13 nM.
Purvalanol B is a cyclin-dependent; 2,6,9-substituted kinase inhibitor.